Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase

Although the majority of patients with chronic myeloid leukemia (CML) enjoy an excellent prognosis tyrosine kinase inhibitor (TKI) therapy, resistance remains a significant clinical problem. Resistance can arise from mutations in the kinase domain of ABL preventing drug binding, or due to ill-define...

Descripción completa

Detalles Bibliográficos
Autores principales: Oyogoa, Emmanuella, Streich, Lukas, Raess, Philipp W., Braun, Theodore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513384/
https://www.ncbi.nlm.nih.gov/pubmed/37746298
http://dx.doi.org/10.3389/fonc.2023.1217153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513384/
https://www.ncbi.nlm.nih.gov/pubmed/37746298
http://dx.doi.org/10.3389/fonc.2023.1217153

Ejemplares similares